“…In the last decade, several studies have documented the omission of certain treatments. A small number of clinical trials omitting radiotherapy for selected groups of older, HR positive patients, have been performed [28] none of them showing a deterred survival. However, the risk of locoregional recurrence was higher, as was also shown in the EBCTCG overview [29], and recently confirmed in the PRIME II trial [30].…”